A team from University Hospitals Seidman Cancer Center is launching the nation’s first-ever clinical trials evaluating the cholesterol drug fenofibrate (Triglide, Fibricor, Lipofen) as an investigational and potential treatment for patients with HPV+ cervical and HPV+ head and neck cancer (HNSCC).
As digital health tech proliferates, a new institute aims to cut through hype
A new $50 million nonprofit initiative aims to independently evaluate health technologies’ impact on costs and quality, an attempt to help patients, payers, and providers